Jennifer Sturgill, DO, Central Ohio Primary Care, discusses how shortages of antibiotics and medications for attention-deficit/hyperactivity disorder have affected primary care, as well as addresses the impact on heart failure care of CMS’ recent announcement of the first 10 drugs up for price negotiation in 2026 under the Inflation Reduction Act (IRA).
Jennifer Sturgill, DO, inpatient medical director of population health, Central Ohio Primary Care, discusses how shortages of antibiotics and medications for attention-deficit/hyperactivity disorder have affected primary care, as well as addresses the impact of CMS’ recent announcement of the first 10 drugs up for price negotiation in 2026 on heart failure care.
She presented on value-based care at our recent Institute for Value-Based Medicine® event held with the Zangmeister Cancer Center of Columbus, Ohio.
Transcript
Can you provide insight into how the current drug shortage has affected primary care for patients?
You know, the drug shortages have mostly been on antibiotics and ADHD [attention-deficit/hyperactivity disorder] medications. The antibiotics are a little bit easier to deal with because we can provide alternatives. And I think it really has kind of forced providers to maybe get out of their comfort zone instead of just always prescribing that one antibiotic they're comfortable with; they can pull up the guidelines and see what's the first, second line and change it to something different.
The ADHD medications have been a little bit more difficult, and that really has been the pressure put on the patient. They're the ones having to go to different pharmacies to find out if the medication is available. We really don't have a great solution or workaround to this. I think it's getting a little bit better, but it's still a huge burden on the patients.
How might CMS’ announcement of the 10 drugs subject to price negotiation under the Inflation Reduction Act affect primary care when negotiated prices take effect?
I'd say not just primary care, but for patients in general, looking at the list, in particular, the SGLT-2 [sodium-glucose cotransporter-2] inhibitors, they are hugely important now in the treatment of CHF. And, you know, we have an aging population, and people are developing congestive heart failure, they're living longer, and they're living longer chronically ill. And now when we're starting patients on medications, we can give them a coupon and hope that they're able to get that first month supply. But it really takes a lot of effort on the patient's behalf and on the primary care provider to make sure that their patient is able to stay on the medication, that there's no interruption in care.
We know that CHF is one of the leading readmission diagnoses for patients. These patients decompensate quickly and often, and it's not helping their medical condition if they're not able to stay on a medication. So, it's very exciting to see that these medications are going to be addressed.
And then the other medications, the anticoagulants with Eliquis [apixaban] and Xarelto [rivaroxaban], we know that these are safer, [have] fewer interactions, require less monitoring than Coumadin [warfarin]. These are the medications we are prescribing for patients, and a lot of patients are on them. And again, it's going to be very helpful to know that we don't necessarily have to jump through a lot of hoops to make sure the patient can initially fill the medication, but then also stay on it.
Robert F. Kennedy Jr Faces Senate Inquiry Over Deep Cuts to HHS Impacting FDA, CDC, NIH, CMS
April 2nd 2025A bipartisan letter from lawmakers questions the legality of Robert F. Kennedy Jr's HHS changes and the lack of clear communication regarding their potential impact on American health.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
How Recent Federal Policy Changes Are Shaping Managed Care Pharmacy
April 2nd 2025Federal legislative and regulatory changes are reshaping pharmacy practice, with key challenges in government funding, pharmacy benefit manager reform, and health care policy shifts—topics explored by experts at the Academy of Managed Care Pharmacy's annual meeting.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Managed Care Reflections: A Q&A With Hoangmai H. Pham, MD, MPH
April 1st 2025To mark the 30th anniversary of The American Journal of Managed Care® (AJMC®), each issue in 2025 will include a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The April issue features a conversation with Hoangmai H. Pham, MD, MPH, a member of AJMC’s editorial board and the president and CEO of the Institute for Exceptional Care (IEC).
Read More